{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:59:21Z","timestamp":1793476761772,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100399","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:28:40Z","timestamp":1645446520000},"page":"100399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"Heitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mouliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"S\u00fcltmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Verstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100399_bib1","doi-asserted-by":"crossref","first-page":"190052","DOI":"10.1183\/16000617.0052-2019","article-title":"Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages","volume":"29","author":"Guibert","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.esmoop.2022.100399_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/resp.13823","article-title":"Is tissue still the issue in detecting molecular alterations in lung cancer?","volume":"25","author":"Liam","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.esmoop.2022.100399_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-030-26439-0_11","article-title":"Capturing tumor heterogeneity and clonal evolution by circulating tumor DNA profiling","volume":"215","author":"Scherer","year":"2020","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib5","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib7","author":"AstraZeneca"},{"key":"10.1016\/j.esmoop.2022.100399_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.21037\/tlcr.2016.08.06","article-title":"Pros: can tissue biopsy be replaced by liquid biopsy?","volume":"5","author":"Ili\u00e9","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib9","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424675","article-title":"Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Giroux Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2022.100399_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226853","article-title":"Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients","volume":"14","author":"Papadopoulou","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2022.100399_bib13","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/clinchem\/hvaa164","article-title":"Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: a joint consensus recommendation of the BloodPAC's Analytical Variables Working Group","volume":"66","author":"Godsey","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.esmoop.2022.100399_bib14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.079","article-title":"Phase II\/III blood-first assay screening trial (BFAST) in treatment-na\u00efve NSCLC: initial results from the ALK+ cohort","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib16","article-title":"Real-world utility of an amplicon-based next-generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non-small-cell lung cancer","volume":"3","author":"Remon","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib18","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib19","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1158\/1078-0432.CCR-16-1231","article-title":"Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA","volume":"22","author":"Thompson","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2019.10.013","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I-IV non-small cell lung cancer","volume":"22","author":"Jiang","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.esmoop.2022.100399_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000872","article-title":"Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer","volume":"5","author":"Perakis","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100399_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.esmoop.2022.100399_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.csbj.2018.10.002","article-title":"Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management","volume":"16","author":"Elazezy","year":"2018","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.esmoop.2022.100399_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib25","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/cancers12061588","article-title":"Technical evaluation of commercial mutation analysis platforms and reference materials for liquid biopsy profiling","volume":"12","author":"Weber","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2022.100399_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","article-title":"Current practices and guidelines for clinical next-generation sequencing oncology testing","volume":"13","author":"Strom","year":"2016","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic - implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib29","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100399_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/diagnostics11010103","article-title":"Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late","volume":"11","author":"IJzerman","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.esmoop.2022.100399_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100399_bib32","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat. Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib33","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1200\/PO.20.00046","article-title":"Clonal hematopoiesis in late-stage non\u2013small-cell lung cancer and its impact on targeted panel next-generation sequencing","author":"Yaung","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/cancers10090290","article-title":"A\u00a0multicenter study to assess EGFR mutational status in plasma: focus on an optimized workflow for liquid biopsy in a clinical setting","volume":"10","author":"Sorber","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2022.100399_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223112","article-title":"Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations","volume":"14","author":"Poole","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2022.100399_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fpubh.2017.00307","article-title":"Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice","volume":"5","author":"Trevethan","year":"2017","journal-title":"Front Public Health"},{"key":"10.1016\/j.esmoop.2022.100399_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00191","article-title":"Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance","volume":"3","author":"Stetson","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41374-020-0459-7","article-title":"Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms","volume":"100","author":"Koessler","year":"2020","journal-title":"Lab Invest"},{"key":"10.1016\/j.esmoop.2022.100399_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1186\/s12885-018-4694-x","article-title":"International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA","volume":"18","author":"Keppens","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib44","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.annonc.2020.03.307","article-title":"Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy?","volume":"31","author":"Bailleux","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib45","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/cancers12082277","article-title":"Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2022.100399_bib46","first-page":"317","article-title":"Clonal hematopoiesis of indeterminate potential","volume":"113","author":"Heuser","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.esmoop.2022.100399_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2022.100399_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100399_bib49","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/PO.21.00182","article-title":"Dynamic changes of circulating tumor DNA predict clinical outcome in patients with advanced non\u2013small-cell lung cancer treated with immune checkpoint inhibitors","author":"Weber","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib50","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/annonc\/mdy513","article-title":"Biological background of the genomic variations of cf-DNA in healthy individuals","volume":"30","author":"Liu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib51","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib52","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1186\/s12885-020-07603-9","article-title":"Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdy552","article-title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","volume":"30","author":"Abbosh","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00428-019-02571-3","article-title":"IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing","volume":"474","author":"Deans","year":"2019","journal-title":"Virchows Archiv"},{"key":"10.1016\/j.esmoop.2022.100399_bib56","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/s41598-019-51459-4","article-title":"eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA","volume":"9","author":"Mizuno","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2022.100399_bib57","doi-asserted-by":"crossref","first-page":"97769","DOI":"10.18632\/oncotarget.22080","article-title":"Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100399_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00318","article-title":"Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non\u2013small-cell lung cancer: a multicenter case series","volume":"28","author":"Jacobs","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cllc.2018.07.008","article-title":"Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor","volume":"19","author":"Helman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib61","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.jtho.2017.08.011","article-title":"Germline mutations in DNA repair genes in lung adenocarcinoma","volume":"12","author":"Parry","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib62","doi-asserted-by":"crossref","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited lung cancer syndromes targeting never smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib63","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.00328","article-title":"Identification of incidental germline mutations in patients with advanced solid tumors who underwent cell-free circulating tumor DNA sequencing","volume":"36","author":"Slavin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib64","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41588-020-0603-8","article-title":"A\u00a0harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer","volume":"52","author":"Wagner","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2022.100399_bib66","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/ijc.32358","article-title":"Variant classification in precision oncology","volume":"145","author":"Leichsenring","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib67","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9103","article-title":"Early mortality in metastatic lung cancer: a SEER population data analysis","volume":"37","author":"Globus","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.5858\/arpa.2016-0163-SA","article-title":"Liquid biopsy in lung cancer: a perspective from members of the Pulmonary Pathology Society","volume":"140","author":"Sholl","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lungcan.2014.08.016","article-title":"Feasibility and clinical impact of re-biopsy in advanced non-small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01)","volume":"86","author":"Chouaid","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib71","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32876","article-title":"Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: analysis of over 8000 cases","volume":"126","author":"Mack","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234302","article-title":"Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay","volume":"15","author":"Remon","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2022.100399_bib73","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-15-1031","article-title":"Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses","volume":"22","author":"Sundaresan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib74","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00330-016-4357-8","article-title":"Complication rates of CT-guided transthoracic lung biopsy: meta-analysis","volume":"27","author":"Heerink","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.esmoop.2022.100399_bib75","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1148\/radiol.13131265","article-title":"C-arm cone-beam CT-guided percutaneous transthoracic needle biopsy of lung nodules: clinical experience in 1108 patients","volume":"271","author":"Lee","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.esmoop.2022.100399_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2214\/AJR.14.13151","article-title":"CT-guided fine-needle aspiration and core needle biopsies of pulmonary lesions: a single-center experience with 750 biopsies in Japan","volume":"204","author":"Takeshita","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.esmoop.2022.100399_bib77","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/1759-7714.12964","article-title":"Questionnaire survey on patient awareness of invasive rebiopsy in advanced non-small cell lung cancer","volume":"10","author":"Fukui","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib78","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/1759-7714.13300","article-title":"Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples","volume":"11","author":"Ma","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib79","first-page":"e4907","article-title":"Potential applications of circulating tumor DNA technology as a cancer diagnostic tool","volume":"11","author":"Kunnath","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.esmoop.2022.100399_bib80","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10555-020-09876-9","article-title":"Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy","volume":"39","author":"Boonstra","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.esmoop.2022.100399_bib81","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100399_bib82","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40291-019-00390-5","article-title":"Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)","volume":"23","author":"Chin","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.esmoop.2022.100399_bib83","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT023","article-title":"Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: a lung TRACERx study","volume":"80","author":"Abbosh","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100399_bib84","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1186\/s12885-020-07252-y","article-title":"Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study","volume":"20","author":"Schraa","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13148-018-0500-5","article-title":"Circulating tumour DNA for monitoring colorectal cancer\u2014a prospective cohort study to assess relationship to tissue methylation, cancer characteristics and surgical resection","volume":"10","author":"Symonds","year":"2018","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.esmoop.2022.100399_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz8084","article-title":"ctDNA monitoring using patient-specific sequencing and integration of variant reads","volume":"12","author":"Wan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib87","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100399_bib88","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/diagnostics10060429","article-title":"Budget impact analysis of EGFR mutation liquid biopsy for first- and second-line treatment of metastatic non-small cell lung cancer in Greece","volume":"10","author":"Cheng","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.esmoop.2022.100399_bib89","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2014.59.2444","article-title":"Genomic characterization of non-small-cell lung cancer in African Americans by targeted massively parallel sequencing","volume":"33","author":"Araujo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib90","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2022.100399_bib91","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccell.2019.09.003","article-title":"Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA","volume":"36","author":"Van der Pol","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100399_bib92","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib93","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-020-17316-z","article-title":"Non-invasive early detection of cancer four years before conventional diagnosis using a blood test","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.esmoop.2022.100399_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.esmoop.2022.100399_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006162","article-title":"Fragment length of circulating tumor DNA","volume":"12","author":"Underhill","year":"2016","journal-title":"PLoS Genet"},{"key":"10.1016\/j.esmoop.2022.100399_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2022.100399_bib97","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100399_bib98","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-018-0058-3","article-title":"Early stage NSCLC \u2013 challenges to implementing ctDNA-based screening and MRD detection","volume":"15","author":"Abbosh","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100399_bib99","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.esmoop.2022.100399_bib101","article-title":"Current advances in clinical application of liquid biopsy. In: Histopathology and Liquid Biopsy","author":"Baldacchino","year":"2021","journal-title":"Rijeka, Croatia: IntechOpen"},{"key":"10.1016\/j.esmoop.2022.100399_bib107","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.18632\/oncotarget.13915","article-title":"Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer","volume":"8","author":"Normanno","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100399_bib108","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jmoldx.2020.05.006","article-title":"Assessment of pre-analytical sample handling conditions for comprehensive liquid biopsy analysis","volume":"22","author":"Gerber","year":"2020","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.esmoop.2022.100399_bib109","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","article-title":"The emerging role of cell-free DNA as a molecular marker for cancer management","volume":"17","author":"Bronkhorst","year":"2019","journal-title":"Biomol Detect Quantif"},{"key":"10.1016\/j.esmoop.2022.100399_bib110","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/cancers12051222","article-title":"Comparison of circulating cell-free DNA extraction methods for downstream analysis in cancer patients","volume":"12","author":"Van der Leest","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2022.100399_bib111","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1373\/clinchem.2019.306837","article-title":"Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows","volume":"66","author":"Lampignano","year":"2020","journal-title":"Clin Chem"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:21Z","timestamp":1761856041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000205"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100399","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100399"}}